Agouron Pharmaceuticals, Inc.

Pfizer Corporation

Novo Nordisk A/s

Atsuo Kuki

Michael Bruno Plewe

Junhu Zhang

Hai Wang

Min Teng

Yufeng Hong

Vlad Edward Gregor

Anthony Lai Ling

Javier Gonzalez

Michael David Johnson

Qiyue Hu

Xinqiang Li

Dan Kiel

Dawn Marie Nowlin

Jesper F Lau

Jun Feng

Peter Madsen

Christian Klarner Sams

Daljit Singh Dhanoa

Lars Naerum

Shenghua Shi

Ted William Johnson

Larry Kenneth Truesdale

Ulla Grove Sidelmann

Lotte Bjerre Knudsen

Ranjan Jagath Rajapakse

Richard A Bychowski

Kimberly Ann Teston

Tso-sheng Chou

Bicycling hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.

HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use

Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.

HIV integrase inhibitors, pharmaceutical compositions and methods for their use

Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.

HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use

Beta-carboline hydroxamic acid compounds represented by formula (I)are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.

Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.

Glucagon antagonists/inverse agonists

Non-peptide compounds that act as antagonists of the intestinal hormone glucagons-like peptide 1 (GLP-1) have a 9H-b-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent activation of the receptor by bound GLP-1. The invention further relates to a method of inhibiting the binding of GLP-1 to the GLP-1 receptor and a method of inhibiting the activation of the GLP-1 receptor. Intermediate compounds useful for making non-peptide GLP-1 receptor antagonists are also described.

Non-peptide antagonists of GLP-1 receptor and methods of use

Growing community of inventors

Encinitas, CA, United States of America

Atsuo Kuki